MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.46
+1.20
+4.95%
After Hours: 25.00 -0.46 -1.81% 19:17 09/16 EDT
OPEN
24.11
PREV CLOSE
24.26
HIGH
25.57
LOW
24.11
VOLUME
461.94K
TURNOVER
--
52 WEEK HIGH
43.32
52 WEEK LOW
9.12
MARKET CAP
2.06B
P/E (TTM)
-9.5078
1D
5D
1M
3M
1Y
5Y
BRIEF-Alector Doses First Participant In Phase 2 Study Of ALS Treatment
reuters.com · 09/09 13:18
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)
Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, ...
GlobeNewswire · 09/09 12:30
BRIEF-Alector Inc Appoints Linda Rubinstein As Co's Interim Chief Financial Officer
reuters.com · 09/08 20:37
GSAT, ATER and PXLW among mid-day movers
Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +...
Seekingalpha · 09/08 17:29
Mid-Day Market Update: Crude Oil Rises 1%; REV Group Shares Plummet
Midway through trading Wednesday, the Dow traded down 0.45% to 34,942.88 while the NASDAQ fell 1.09% to 15,207.45. The S&P also fell, dropping 0.55% to 4,495.35.
Benzinga · 09/08 16:17
Sector Update: Health Care
MT Newswires · 09/08 15:59
Kadmon, ICU Medical leads healthcare gainers; INmune Bio, Inozyme Pharma among major losers
Gainers: Kadmon (NASDAQ:KDMN) +73%, ICU Medical (NASDAQ:ICUI) +32%, Candel Therapeutics (NASDAQ:CADL) +17%, Gain Therapeutics (NASDAQ:GANX) +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -1...
Seekingalpha · 09/08 14:58
Mid-Morning Market Update: Markets Mixed; Korn Ferry Reports Upbeat Q1 Results
Following the market opening Wednesday, the Dow traded up 0.03% to 35,111.48 while the NASDAQ fell 0.27% to 15,332.05. The S&P also fell, dropping 0.02% to 4,519.29.
Benzinga · 09/08 14:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALEC stock price target is 44.00 with a high estimate of 57.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 53.94M
% Owned: 66.69%
Shares Outstanding: 80.88M
TypeInstitutionsShares
Increased
48
5.47M
New
28
783.67K
Decreased
29
2.89M
Sold Out
16
508.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President/Chief Operating Officer
Shehnaaz Suliman
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Chief Financial Officer/Chief Accounting Officer
Linda Rubinstein
Vice President - Finance
Calvin Yu
Other
Robert King
Other
Robert Paul
Lead Director/Independent Director
Louis Lavigne
Independent Director
Paula Hammond
Independent Director
Terry Mcguire
Independent Director
Richard Scheller
Independent Director
David Wehner
Independent Director
Kristine Yaffe
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL002, AL003, and AL101. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.